Syngene Results Q1 FY26: First quarter revenue from operations up 11% year-on-year to Rs. 875 Cr
- Sub Editor
- Jul 23
- 3 min read
Positive start to the financial year
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Syngene International Limited today announced results for the first quarter of FY26.
Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins)
| Q1 FY25 | Q1 FY26 | YoY Change (%) |
Revenue from Operations | 790 | 875 | 11% |
Reported Revenue | 808 | 892 | 10% |
Reported EBITDA | 188 | 224 | 19% |
Reported EBITDA margin (%) | 23% | 25% | - |
Reported PAT (before exceptional items) | 54* | 87 | 59% |
Reported PAT Margin (%) | 7% | 10% | - |
*Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim.
Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum. In our Biologics manufacturing division, we have seen good progress with the start of operations at the Unit III facility in Bengaluru and in advancing preparations to commence operations at our Bayview facility in the U.S later this year. We continued to strengthen and expand our scientific platform capabilities, bringing online a state-of-the-art, dedicated peptide laboratory. While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook.”
Deepak Jain, Chief Financial Officer, Syngene International Limited, said, “We are pleased with the growth in revenue from operations of 11% year-on-year. Operating EBITDA margins came at around 24%, driven by both revenue growth and a focus on cost optimisation. The current quarter’s PAT includes a tax benefit arising from transfer of gratuity funds to Employee Gratuity Trust. We continue to maintain a robust balance sheet enabling us to invest in technology and capabilities to strengthen our customer offerings. While keeping a close watch on market trends, we remain on course to deliver in line with our stated guidance for the year.”
Key Business Highlights:
Syngene successfully completed a USFDA Good Clinical Practices (GCP) inspection of its Human Pharmacology Unit with no observations. The Company’s Biologics facility at Biocon Park received an Establishment Inspection Report (EIR) with a favourable Voluntary Action Indicated (VAI) outcome. Additionally, the Company concluded over 20 client and regulatory audits in Q1 FY26, reinforcing its commitment to global quality and integrity standards.
Syngene inaugurated its new, state-of-the-art, dedicated peptide laboratory. Peptides are a fast-growing interventional modality that also complement Syngene’s existing capabilities in monoclonal antibodies, Antibody-Drug Conjugates, Oligonucleotides and PROTACs (proteolysis targeting chimeras).
Syngene was recognised by TIME magazine and Statista as one of the World’s Most Sustainable Companies in 2025. Syngene ranked #1 in India among companies in the pharma and biotech sectors and was ranked in the top 20 lifescience companies globally. Chosen from a pool of over 5,700 global organisations, this recognition underscores the Company’s steadfast commitment to environmental care and social responsibility.
Earnings Call: Syngene will host an investor call at 12:15 pm IST on July 24, 2025, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1279 / +91 22 7115 8180. Participants can also join the call via this webcast link. Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available until 31 July, 2025, on +91 22 71945757, Playback ID: 95617. We will aim to post the transcript of the conference call on the company website within seven working days of the investor conference call.
About Syngene
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and speciality chemical sectors. Syngene’s team of over 5,600 scientists brings both deep expertise and the capacity to deliver scientific excellence, robust data security and world-class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.5+ mn sq. ft of specialised discovery, development, and manufacturing facilities, Syngene works with around 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com.
For the Company’s latest Environmental, Social, and Governance (ESG) report, visit https://esgreport.syngeneintl.com.
Reach out to us at the PR Desk
Read more on our Partner sites: Dais World | The Progress Catalyst
Get rewarded for your reading habits on the Dais World app!
